Table 1 displays the clinical features of the samples from the two groups. In ccRCC, more examination of the relationship and impact of ACSL3 on patient survival was undertaken. This was accomplished via the usage of the GEPIA datasets. A lower level of ACSL3 was related to a shorter overall survival (OS, P = 0.0051) and disease-free survival (DFS, P = 0.0045) in ccRCC patients, demonstrating that down-regulated ACSL3 expression was a risk factor for a worse prognosis in ccRCC patients (Figures 5A,B). This evidence concerns the gene ACSL3 and nonpapillary renal cell carcinoma.